MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2024 International Congress

    Demographics of Botulinum toxin therapy population representative to demographics in Essex County, USA

    B. Puccio, Y. Xu, J. Acquaviva, E. Feinstein (Newark, USA)

    Objective: To describe and compare the demographics of patients receiving botulinum toxin therapy in a single movement disorder clinic to the broader surrounding community. Background:…
  • 2024 International Congress

    Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach

    M. Hildaria, D. Tunjungsari, A. Tiksnadi (Central Jakarta, Indonesia)

    Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…
  • 2024 International Congress

    Disparities in Botulinum Toxin Utilization for Cervical Dystonia in a United States Medicare Population

    M. Verduzco-Gutierrez, A. Keener, I. Howard, D. Torres-Russotto, J. Sparrow, R. Kazerooni (San Antonio, USA)

    Objective: To examine the disparities in utilization of botulinum toxin (BoNT) injections for patients with cervical dystonia (CD) within the United States Medicare population. Background:…
  • 2024 International Congress

    Perceptions of Diseases in Patients with Cervical Dystonia

    D. Talkington, D. Sblendorio, K. Pyle, M. Coleman, M. Patel, M. Moreno-Escobar, A. Murray, A. Memon, J. Frey (Morgantown, USA)

    Objective: To explore how perception of disease can impact stigma, mood, quality of life, and severity of symptoms in patients with cervical dystonia (CD). Background:…
  • 2024 International Congress

    Botulinum Toxin and Deep Brain Stimulation in Dystonia

    J. Souza, A. Falcone, R. Barbosa, M. Soares, R. Munhoz, M. Farah, T. Capato, S. Casagrande, M. Cordellini, G. Micheli, J. Limongi, E. Barbosa, C. Listik, R. Cury (Sao Paulo, Brazil)

    Objective: The primary outcome was the relationship between BoNT dosage and DBS surgery in each muscle. A secondary analysis of BoNT dosages through different muscle…
  • 2024 International Congress

    Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?

    A. Kundrick, H. Fernandez (Cleveland, USA)

    Objective: To determine if there is a difference in efficacy and duration of effect between high-dose and low-dose botulinumtoxin neurotoxin type-A for cervical dystonia. Background:…
  • 2023 International Congress

    Real-world retrospective safety analysis of onabotulinumtoxinA for the treatment of patients with concurrent cervical dystonia and chronic migraine

    C. Rhyne, K. Martinez, J. Stoilova, A. Patel, K. Becker Ifantides, R. Singh, I. Yushmanova, M. Sadeghi, S. Battucci, G. Forde (Chicago, USA)

    Objective: To assess the real-world safety of onabotulinumtoxinA (onabotA) for the concomitant treatment of cervical dystonia (CD) and chronic migraine (CM). Background: In the United…
  • 2023 International Congress

    Pain and quality of life in cervical dystonia

    L. Herrmann, L. Vorbeck, A. Palisi, A. Maurer, S. Lezius, J. Mallwitz, M. Gelderblom, S. Zittel (Hamburg, Germany)

    Objective: To evaluate different aspects of quality of life (QoL) and pain prevalence, characteristics and influencing factors in patients with cervical dystonia (CD) before and…
  • 2023 International Congress

    Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients with Cervical Dystonia in the US

    K. Dashtipour, D. Charles, M. Sadeghi, M. Heath, A. Rava, J. Liu, H. Sun, Y. Dong, J. Lee (Loma Linda, USA)

    Objective: To compare health care resource utilization (HCRU) and costs among patients with cervical dystonia (CD) in the US who are persistent vs nonpersistent with…
  • 2023 International Congress

    Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

    Objective: This study aimed to evaluate the clinical spectrum of patients with dystonia seen at Cleveland Clinic Abu Dhabi Hospital (CCAD), a tertiary care center…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley